A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study

The METTEN study assessed the efficacy, tolerability, and safety of adding metformin to neoadjuvant chemotherapy plus trastuzumab in early HER2-positive breast cancer (BC). Women with primary, non-metastatic HER2-positive BC were randomized (1:1) to receive metformin (850 mg twice-daily) for 24 week...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Castillo, Begoña, Pernas, Sonia, Dorca, Joan, Álvarez, Isabel, Martínez, Susana, Pérez-Garcia, Jose Manuel, Batista-López, Norberto, Rodríguez-Sánchez, César A., Amillano, Kepa, Domínguez, Severina, Luque, Maria, Stradella, Agostina, Morilla, Idoia, Viñas, Gemma, Cortés, Javier, Cuyàs, Elisabet, Verdura, Sara, Fernández-Ochoa, Álvaro, Fernández-Arroyo, Salvador, Segura-Carretero, Antonio, Joven, Jorge, Pérez, Elsa, Bosch, Neus, Garcia, Margarita, López-Bonet, Eugeni, Saidani, Samiha, Buxó, Maria, Menendez, Javier A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235018/
https://www.ncbi.nlm.nih.gov/pubmed/30479698
http://dx.doi.org/10.18632/oncotarget.26286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235018/
https://www.ncbi.nlm.nih.gov/pubmed/30479698
http://dx.doi.org/10.18632/oncotarget.26286

Ejemplares similares